Twenty-eight patients with tinea capitis, tinea corporis, and/or onychomycosis who were treated with oral griseofulvin (250 mg. four times daily) were studied intensively. The following tests were performed as indicated.
Complete blood count
Routine urine examination
Before and after one month medication:
Bone marrow examination
Blood urea nitrogen
Testicular biopsy (two)
Complete blood counts and bone marrow studies were repeated six weeks after termination of treatment, in each case.
In addition, patch tests were performed on 200 individuals, including 28 who had previously received griseofulvin internally. A water-soluble base containing 5% griseofulvin was used. The base, alone, was used as a control.
All laboratory tests, except the white blood counts, remained essentially unchanged throughout the course of treatment.In 18 (64.3%) patients, a decrease of 10%
Mc CUISTION CH, LAWLIS M, GONZALES BB. Human Pharmacological Studies with Griseofulvin. AMA Arch Derm. 1960;81(5):766–768. doi:10.1001/archderm.1960.03730050122021
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: